ÀÌ»óÇ÷»ö¼ÒÁõ ½ÃÀå ±âȸ¿Í ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Hemoglobinopathies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1621752
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 165 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÌ»óÇ÷»ö¼ÒÁõ ¼¼°è ½ÃÀåÀº 2023³â 63¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, Çì¸ð±Û·Îºó °ü·Ã Áúȯ Áõ°¡, À¯ÀüÀÚ ¿¬±¸ ½ÃÀå °³Ã´, »õ·Î¿î Ä¡·á¹ý °³¹ß·Î ÀÎÇØ 2024-2032³â°£ ¿¬Æò±Õ 10.4%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Çì¸ð±Û·Îºó ÀÌ»ó Áúȯ¿¡´Â °â»óÀûÇ÷±¸Áõ(SCD), ÁöÁßÇØ ºóÇ÷ µî ÀûÇ÷±¸ ³» »ê¼Ò ¿î¹Ý ´Ü¹éÁúÀÎ Çì¸ð±Û·ÎºóÀÇ ±¸Á¶¿Í ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯ÀüÀû ÁúȯÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ »ê¾÷Àº ÀÌ·¯ÇÑ À¯Àü¼º Ç÷¾×ÁúȯÀÇ Áø´Ü, Ä¡·á, °ü¸® ¹× Áõ»ó ¿ÏÈ­¿Í ¿ÏÄ¡ °¡´É¼ºÀ» ¸ñÇ¥·Î ÇÏ´Â ÀǾàǰ, À¯ÀüÀÚ Ä¡·á, Áø´Ü °Ë»ç, ¼öÇ÷ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº Áúȯ À¯Çü¿¡ µû¶ó ÁöÁßÇØ ºóÇ÷°ú SCD·Î ºÐ·ùµÇ¸ç, ÁöÁßÇØ ºóÇ÷Àº ´Ù½Ã ¥áÇü°ú ¥âÇüÀ¸·Î ³ª´¹´Ï´Ù.

2023³â¿¡´Â SCD°¡ 33¾ï ´Þ·¯·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, SCD Ä¡·á¿¡´Â ¼öÇ÷, ÅëÁõ °ü¸®, ÇÏÀ̵å·Ï½Ã¿ì·¹¾Æ µîÀÌ Æ÷ÇԵǸç, À¯ÀüÀÚ Ä¡·á¿Í CRISPRÀ» ÀÌ¿ëÇÑ Á¢±Ù¹ýÀÇ ¹ßÀüÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à »ê¾÷°ú Á¤ºÎÀÇ ÀçÁ¤Àû Áö¿øÀº Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Ä¡·á À¯Çüº°·Î´Â ¼öÇ÷, ÇÏÀ̵å·Ï½Ã¿ì·¹¾Æ, öºÐ ų·¹ÀÌÆ® ¿ä¹ý, °ñ¼ö ÀÌ½Ä ¹× ±âŸ ¹æ¹ýÀ¸·Î ½ÃÀåÀÌ ³ª´¹´Ï´Ù.

¼öÇ÷Àº 2023³â ½ÃÀåÀÇ 43.1%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ƯÈ÷ ÁöÁßÇØ ºóÇ÷À̳ª SCD¿Í °°Àº Áúȯ¿¡¼­ ¿©ÀüÈ÷ Áß¿äÇÑ Ä¡·á¹ýÀÔ´Ï´Ù. ÀÌ Ä¡·á¹ýÀº ºóÇ÷À» ¿ÏÈ­Çϰí ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϸç ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±Çϱâ À§ÇØ °Ç°­ÇÑ ÀûÇ÷±¸¸¦ Á¤±âÀûÀ¸·Î ¼öÇ÷ÇÏ´Â °ÍÀÔ´Ï´Ù. ¼öÇ÷ ¿ä¹ýÀº ÷´Ü Ä¡·á ¿É¼ÇÀ» ÀÌ¿ëÇϱ⠾î·Á¿î °³¹ßµµ»ó±¹¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2032³â±îÁö ¿¬Æò±Õ 10%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 57¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ±Ô¸ð
½ÃÀå ±Ô¸ð
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024³â-2032³â
½ÃÀÛ ±Ý¾× 63¾ï ´Þ·¯
¿¹»ó ±Ý¾× 153¾ï ´Þ·¯
CAGR 10.4%

¹Ì±¹ ÀÌ»óÇ÷»ö¼ÒÁõ ½ÃÀåÀÇ ¼ºÀåÀº ÀÎ½Ä °³¼±, Á¶±â Áø´Ü, SCD ¹× ÁöÁßÇØ ºóÇ÷°ú °°Àº Áúȯ¿¡ ´ëÇÑ Ã·´Ü Ä¡·á¹ý µµÀÔ¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °­·ÂÇÑ ÀÇ·á ÀÎÇÁ¶ó´Â À¯ÀüÀÚ Ä¡·á ¹× Â÷¼¼´ë ½ÃÄö½ÌÀ» Æ÷ÇÔÇÑ Ã·´Ü Áø´Ü ±â¼úÀÇ ½Å¼ÓÇÑ ÅëÇÕÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½Å»ý¾Æ °ËÁø ÇÁ·Î±×·¥°ú °°Àº Á¤ºÎ ÁÖµµÀÇ ³ë·Âµµ Á¶±â ¹ß°ßÀ²À» ³ôÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±Çϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÷´Ü Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ ¹× »ê¾÷°èÀÇ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ÀÌ»óÇ÷»ö¼ÒÁõ ½ÃÀåÀº Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº »ý¸í¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Ç÷¾× ÁúȯÀÇ Áø´Ü, Ä¡·á ¹× Àü¹ÝÀûÀÎ °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ Àü ¼¼°èÀûÀÎ ³ë·Â°ú ÀÏÄ¡ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áúȯ À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Ä¡·áº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦9Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Hemoglobinopathies Market was valued at USD 6.3 billion in 2023 and is anticipated to grow at a CAGR of 10.4% from 2024 to 2032, driven by a rise in hemoglobin associated diseases, developments in genetic research, and new therapeutic inventions. Hemoglobinopathies encompass genetic conditions such as sickle cell disease (SCD) and thalassemia that affect the structure and function of hemoglobin, the protein responsible for oxygen transport in red blood cells. This industry spans the diagnosis, treatment, and management of these inherited blood disorders, offering pharmaceuticals, gene therapies, diagnostic tests, and blood transfusion services aimed at both symptomatic relief and potential cures. The market is segmented by disease type into categories like thalassemia and SCD, with thalassemia further divided into alpha and beta forms.

In 2023, SCD accounted for the largest share of the market, valued at USD 3.3 billion. Treatments for SCD include blood transfusions, pain management, and hydroxyurea, with promising advancements in gene therapy and CRISPR-based approaches. Support from the pharmaceutical sector and government funding is fostering the development of innovative treatment options. In terms of treatment type, the market is divided into blood transfusion, hydroxyurea, iron chelation therapy, bone marrow transplant, and other methods.

Blood transfusions represented a notable 43.1% of the market in 2023 and remain a crucial treatment, especially in conditions like thalassemia and SCD. This therapy involves the regular transfusion of healthy red blood cells to alleviate anemia, minimize complications, and improve patients' quality of life. Blood transfusion therapy is particularly vital in developing regions, where advanced treatment options may be less accessible. Regionally, North America is poised to grow at 10% CAGR through 2032, with the market expected to reach USD 5.7 billion.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$6.3 Billion
Forecast Value$15.3 Billion
CAGR10.4%

U.S. hemoglobinopathies market growth is supported by enhanced awareness, early diagnosis, and the adoption of advanced treatments for conditions like SCD and thalassemia. The region's strong healthcare infrastructure facilitates rapid integration of cutting-edge diagnostic technologies, including gene therapies and next-generation sequencing. Government-led initiatives, such as newborn screening programs, are also improving early detection rates, significantly boosting patient outcomes. With a growing demand for effective treatments and increased government and industry investment in advanced therapies, the hemoglobinopathies market is set for substantial expansion.

This growth aligns with global efforts to improve the diagnosis, treatment, and overall management of these life-impacting blood disorders.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â